Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Urinary Tract Infections D014552 11 associated lipids
Pregnancy Complications, Infectious D011251 11 associated lipids
Otitis Media D010033 12 associated lipids
Acquired Immunodeficiency Syndrome D000163 12 associated lipids
Endophthalmitis D009877 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Eye Diseases D005128 12 associated lipids
Cat Diseases D002371 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Crohn Disease D003424 12 associated lipids
Wound Infection D014946 12 associated lipids
Sarcoidosis D012507 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Pain, Postoperative D010149 13 associated lipids
Airway Obstruction D000402 13 associated lipids
Urticaria D014581 13 associated lipids
Rosacea D012393 13 associated lipids
Abscess D000038 13 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Angina, Unstable D000789 14 associated lipids
Stomatitis D013280 14 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Neutropenia D009503 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Blister D001768 16 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Peptic Ulcer D010437 19 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Hyperglycemia D006943 21 associated lipids
Bacterial Infections D001424 21 associated lipids
Vomiting D014839 21 associated lipids
Helicobacter Infections D016481 21 associated lipids
Periodontitis D010518 22 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Birth Weight D001724 23 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Drug Eruptions D003875 30 associated lipids
Diarrhea D003967 32 associated lipids
Acute Lung Injury D055371 33 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Burns D002056 34 associated lipids
Fever D005334 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Lung Diseases D008171 37 associated lipids
Hypotension D007022 41 associated lipids
Arthritis D001168 41 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Psoriasis D011565 47 associated lipids
Fatty Liver D005234 48 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Pain D010146 64 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Colitis D003092 69 associated lipids
Coronary Disease D003327 70 associated lipids
Stomach Ulcer D013276 75 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Weight Gain D015430 101 associated lipids
Inflammation D007249 119 associated lipids
Hemolysis D006461 131 associated lipids
Edema D004487 152 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Motohiro T et al. [Clinical study on azithromycin in 10% fine granules and 100mg capsules in the field of pediatrics]. 1997 Jpn J Antibiot pmid:9634360
Nachbaur D et al. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. 1997 Bone Marrow Transplant. pmid:9208124
Luke DR and Foulds G Disposition of oral azithromycin in humans. 1997 Clin. Pharmacol. Ther. pmid:9209246
Herrera-Insúa I et al. Synergistic effect of azithromycin on the phagocytic killing of Staphylococcus aureus by human polymorphonuclear leukocytes. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9063667
Pascual A et al. Azithromycin uptake by tissue cultured epithelial cells. 1997 J. Antimicrob. Chemother. pmid:9069561
Khan WA et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. 1997 Ann. Intern. Med. pmid:9139555
Yasin RM et al. Comparison of E-test with agar dilution methods in testing susceptibility of N. gonorrhoeae to azithromycin. 1997 Sex Transm Dis pmid:9153733
Mosby JA Treating acute bronchitis with azithromycin. 1997 Am Fam Physician pmid:9054218
Blanshard C et al. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. 1997 Int J STD AIDS pmid:9061412
Dudle G et al. [Meningitis after acute Borrelia burgdorferi infection in HIV infection]. 1997 Dtsch. Med. Wochenschr. pmid:9378035
Dautzenberg B Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease. 1997 Drugs pmid:9358194
Cohn DL Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. 1997 Drugs pmid:9358195
Marone P et al. Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. 1997 J Chemother pmid:9269603
Gruber F et al. Comparative trial of azithromycin and ciprofloxacin in the treatment of gonorrhea. 1997 J Chemother pmid:9269606
Jepras RI et al. Rapid assessment of antibiotic effects on Escherichia coli by bis-(1,3-dibutylbarbituric acid) trimethine oxonol and flow cytometry. 1997 Antimicrob. Agents Chemother. pmid:9303401
Rodríguez-Bano J et al. [Penetration of azithromycin into human neutrophils: effect of hydrogen peroxide production]. 1997 Enferm. Infecc. Microbiol. Clin. pmid:9312278
Malizia T et al. Periodontal tissue disposition of azithromycin. 1997 J. Periodontol. pmid:9444596
Nguyen MH et al. Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9447909
Nyström-Rosander C et al. Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations. 1997 Scand. J. Infect. Dis. pmid:9435043
Biebuyck XA Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group. 1996 Sep-Oct J. Int. Med. Res. pmid:8895044
Peeling RW and Brunham RC Chlamydiae as pathogens: new species and new issues. 1996 Oct-Dec Emerging Infect. Dis. pmid:8969247
Ripa S et al. A linear model for the pharmacokinetics of azithromycin in healthy volunteers. 1996 Nov-Dec Chemotherapy pmid:8957574
D'Amico R ICAAC update on opportunistic infections. 1996 Nov-Dec Posit Aware pmid:11363974
Wendel TD 1-day azithromycin was as effective as 7-day doxycycline for nongonococcal urethritis syndrome in men. 1996 Nov-Dec ACP J. Club pmid:8912627
Carlin EM and Barton SE Azithromycin as the first-line treatment of non-gonococcal urethritis (NGU): a study of follow-up rates, contact attendance and patients' treatment preference. 1996 May-Jun Int J STD AIDS pmid:8799780
Shanks GD et al. Azithromycin prophylaxis prevents epidemic dysentery. 1996 May-Jun Trans. R. Soc. Trop. Med. Hyg. pmid:8758091
Adam D et al. Re: A. Bauernfeind et al.: Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens (Infection 23 [1995] 316-321) 1996 May-Jun Infection pmid:8811372
Vranes J Effect of subinhibitory concentrations of ceftazidime, ciprofloxacin, and azithromycin on the hemagglutination and adherence of uropathogenic Escherichia coli strains. 1996 May-Jun Chemotherapy pmid:8983884
Ichimiya T et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. 1996 May-Jun Chemotherapy pmid:8983885
Galova K et al. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. 1996 May-Jun Chemotherapy pmid:8983893
Burke SM Azithromycin: only once a day. 1996 May-Jun MCN Am J Matern Child Nurs pmid:8857402
Diculencu D et al. [The postantibiotic effect of azithromycin on respiratory pathogens]. 1996 Jul-Dec Rev Med Chir Soc Med Nat Iasi pmid:9455450
Ehret JM et al. A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. 1996 Jul-Aug Sex Transm Dis pmid:8836018
Lane G Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin. 1996 Jul-Aug Ann Pharmacother pmid:8826581
Amsden GW Erythromycin, clarithromycin, and azithromycin: are the differences real? 1996 Jan-Feb Clin Ther pmid:8851453
Preac Mursic V et al. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. 1996 Jan-Feb Infection pmid:8852456
Baradaran-Dilmaghani R and Stanek G In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. 1996 Jan-Feb Infection pmid:8852472
Strle F et al. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. 1996 Jan-Feb Infection pmid:8852473
Fontán PA et al. Haemophilus influenzae type b exoproducts induce chemotaxis and macrolide antibiotic release by human polymorphonuclear leukocytes. 1996 Jan-Feb Chemotherapy pmid:8751269
Brihmer C et al. Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. 1996 Scand. J. Infect. Dis. pmid:8953672
Van Bambeke F et al. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. 1996 Eur. J. Pharmacol. pmid:8957238
Montenez JP et al. Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. 1996 Eur. J. Pharmacol. pmid:8957239
Prescott LM Macrolides, azalides, and streptogrammins. 1996 J Int Assoc Physicians AIDS Care pmid:11363516
Currier J Progress report: prophylaxis and therapy for MAC. 1996 AIDS Clin Care pmid:11363599
Kuzman I et al. Azithromycin in the treatment of pneumonias caused by Chlamydia spp: a retrospective study. 1996 Int J Clin Pharmacol Res pmid:9172008
Old drug approved for MAC prevention. 1996 AIDS Alert pmid:11363659
Torres G MAC prophylaxis revisited. 1996 GMHC Treat Issues pmid:11363706
Antivirals key to MAC prevention regimen. 1996 AIDS Alert pmid:11363722
Marco M Opportunistic infections in Vancouver. 1996 GMHC Treat Issues pmid:11363841
Azithromycin effective in preventing MAC. 1996 AIDS Alert pmid:11363857
Schouten JT and Whittemore S Recent development in the treatment and prevention of disseminated Mycobacterium avium complex (MAC). 1996 STEP Perspect pmid:11364267
Wittner M et al. Atovaquone in the treatment of Babesia microti infections in hamsters. 1996 Am. J. Trop. Med. Hyg. pmid:8780464
Apseloff G et al. Severe neutropenia caused by recommended prophylactic doses of rifabutin. 1996 Lancet pmid:8782773
ZaÄ­tseva EA et al. [Comparative study of the antimicrobial activity of pefloxacin, ciprofloxacin, norfloxacin and azithromycin with respect to Strains of Yersinia pseudotuberculosis]. 1996 Antibiot. Khimioter. pmid:8762820
Lode H et al. Azithromycin--review of key chemical, pharmacokinetic and microbiological features. 1996 J. Antimicrob. Chemother. pmid:8818841
Girard AE et al. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. 1996 J. Antimicrob. Chemother. pmid:8818842
Girard D et al. Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues. 1996 J. Antimicrob. Chemother. pmid:8818843
Foulds G et al. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. 1996 J. Antimicrob. Chemother. pmid:8818844
Vaudaux BP et al. Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. 1996 J. Antimicrob. Chemother. pmid:8818845
Pukander J and Rautianen M Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. 1996 J. Antimicrob. Chemother. pmid:8818846
Worth S et al. Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials. 1996 Diagn. Microbiol. Infect. Dis. pmid:9147914
Hultén K et al. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. 1996 Antimicrob. Agents Chemother. pmid:9124830
Hicks P et al. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. 1996 J. Pediatr. pmid:8765631
Boran M et al. Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. 1996 Transplant. Proc. pmid:8769234
Luft BJ et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. 1996 Ann. Intern. Med. pmid:8610947
Ridgway GL Azithromycin in sexually transmitted diseases. 1996 Int J STD AIDS pmid:8652719
Young LS Azithromycin in the management of opportunistic infections. 1996 Int J STD AIDS pmid:8652721
Chang HR The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. 1996 Int J STD AIDS pmid:8652722
Waugh MA Azithromycin in gonorrhoea. 1996 Int J STD AIDS pmid:8652723
Young LS Treatment and prophylaxis of Mycobacterium avium complex. 1996 Int J STD AIDS pmid:8652724
Hoepelman IM Human cryptosporidiosis. 1996 Int J STD AIDS pmid:8652725
McCutchan JA Azithromycin in the prophylaxis of opportunistic infections in AIDS. 1996 Int J STD AIDS pmid:8652726
Ridgway GL Azithromycin in the management of Chlamydia trachomatis infections. 1996 Int J STD AIDS pmid:8652727
Furukawa S and Okada T [A clinical evaluation of azithromycin in the treatment of pediatric infection]. 1996 Jpn J Antibiot pmid:8988413
Ballard RC et al. Treatment of chancroid with azithromycin. 1996 Int J STD AIDS pmid:8652728
Okada T et al. [Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field]. 1996 Jpn J Antibiot pmid:8988414
Ishida Y et al. [Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8988415
Ohtsuka Y et al. [Pharmacokinetic and clinical studies on azithromycin in children]. 1996 Jpn J Antibiot pmid:8988416
MashkilleÄ­son AL [The treatment of early syphilis today]. 1996 Ter. Arkh. pmid:9045378
Luke DR et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8913468
Olsen KM et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. 1996 Antimicrob. Agents Chemother. pmid:8913469
Magid D et al. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. 1996 Ann. Intern. Med. pmid:8554247
Cammarota G et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. 1996 Aliment. Pharmacol. Ther. pmid:8971300
Pilotto A et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. 1996 Aliment. Pharmacol. Ther. pmid:8971305
Andenaes K et al. Preoperative bacterial colonization and its influence on postoperative wound infections in plastic surgery. 1996 J. Hosp. Infect. pmid:8971618
Pozniak A and Nelson MR Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. 1996 Genitourin Med pmid:8976832
Schwartz RA et al. Bacillary angiomatosis in an HIV seronegative patient on systemic steroid therapy. 1996 Br. J. Dermatol. pmid:8977724
Griffith DE et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. 1996 Clin. Infect. Dis. pmid:8922790
Chulig I [Pharmacokinetic profile of azithromycin. Role in the treatment of genital Chlamydia infections]. 1996 Antibiot. Khimioter. pmid:8929112
Kuznetsova SM ["Sumamed in the treatment of urogenital infections"]. 1996 Antibiot. Khimioter. pmid:8929115
Skripkin IuK et al. [The problem of diagnosis and treatment of urogenital chlamydiosis in Russia]. 1996 Antibiot. Khimioter. pmid:8929120
Vasil'ev MM and Gazarian IIu [Clinico-laboratory evaluation of the effectiveness of azithromycin in the treatment of patients with Chlamydia and mixed Chlamydia-gonorrhea infections]. 1996 Antibiot. Khimioter. pmid:8929122
Schaad UB and Heynen G Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group. 1996 Pediatr. Infect. Dis. J. pmid:8878223
McLinn S and Williams D Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media. 1996 Pediatr. Infect. Dis. J. pmid:8878239
McCarty J A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. 1996 Pediatr. Infect. Dis. J. pmid:8878240
Aronovitz G A multicenter, open label trial of azithromycin vs. amoxicillin/ clavulanate for the management of acute otitis media in children. 1996 Pediatr. Infect. Dis. J. pmid:8878241
McLinn S A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children. 1996 Pediatr. Infect. Dis. J. pmid:8878242
Khurana CM A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. 1996 Pediatr. Infect. Dis. J. pmid:8878243
Powers JL Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. 1996 Pediatr. Infect. Dis. J. pmid:8878244
Wenisch C et al. Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. 1996 Antimicrob. Agents Chemother. pmid:8878577